These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 25164989)

  • 1. Huntingtin-lowering strategies in Huntington's disease: antisense oligonucleotides, small RNAs, and gene editing.
    Aronin N; DiFiglia M
    Mov Disord; 2014 Sep; 29(11):1455-61. PubMed ID: 25164989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivering a disease-modifying treatment for Huntington's disease.
    Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
    Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
    Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
    Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Huntingtin holiday": progress toward an antisense therapy for Huntington's disease.
    Lu XH; Yang XW
    Neuron; 2012 Jun; 74(6):964-6. PubMed ID: 22726826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.
    Kordasiewicz HB; Stanek LM; Wancewicz EV; Mazur C; McAlonis MM; Pytel KA; Artates JW; Weiss A; Cheng SH; Shihabuddin LS; Hung G; Bennett CF; Cleveland DW
    Neuron; 2012 Jun; 74(6):1031-44. PubMed ID: 22726834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.
    van Bilsen PH; Jaspers L; Lombardi MS; Odekerken JC; Burright EN; Kaemmerer WF
    Hum Gene Ther; 2008 Jul; 19(7):710-9. PubMed ID: 18549309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
    Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
    Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
    Miniarikova J; Evers MM; Konstantinova P
    Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huntingtin-lowering strategies for Huntington's disease.
    Barker RA; Fujimaki M; Rogers P; Rubinsztein DC
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1125-1132. PubMed ID: 32745442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleic Acid Therapeutics in Huntington's Disease.
    Singh K; Roy I
    Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Huntingtin Lowering Strategies.
    Marxreiter F; Stemick J; Kohl Z
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.
    Yu D; Pendergraff H; Liu J; Kordasiewicz HB; Cleveland DW; Swayze EE; Lima WF; Crooke ST; Prakash TP; Corey DR
    Cell; 2012 Aug; 150(5):895-908. PubMed ID: 22939619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using non-coding small RNAs to develop therapies for Huntington's disease.
    Zhang Y; Friedlander RM
    Gene Ther; 2011 Dec; 18(12):1139-49. PubMed ID: 22158031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
    Pfister EL; Kennington L; Straubhaar J; Wagh S; Liu W; DiFiglia M; Landwehrmeyer B; Vonsattel JP; Zamore PD; Aronin N
    Curr Biol; 2009 May; 19(9):774-8. PubMed ID: 19361997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients.
    Skotte NH; Southwell AL; Østergaard ME; Carroll JB; Warby SC; Doty CN; Petoukhov E; Vaid K; Kordasiewicz H; Watt AT; Freier SM; Hung G; Seth PP; Bennett CF; Swayze EE; Hayden MR
    PLoS One; 2014; 9(9):e107434. PubMed ID: 25207939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
    Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
    J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.
    Østergaard ME; Southwell AL; Kordasiewicz H; Watt AT; Skotte NH; Doty CN; Vaid K; Villanueva EB; Swayze EE; Bennett CF; Hayden MR; Seth PP
    Nucleic Acids Res; 2013 Nov; 41(21):9634-50. PubMed ID: 23963702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.